Norm Hovijitra, Partner, Wilson Sonsini
Dr. Norm Hovijitra is a partner in the technology transactions practice at Wilson Sonsini. He advises emerging and established companies in the life sciences industry on legal and business issues associated with the development, manufacture, and commercialization of their products and technologies, including matters relating to intellectual property strategy and patents. Norm’s practice focuses on the representation of clients in complex partnering and licensing arrangements, merger and acquisition transactions, and spin-outs. In addition, he advises clients on a range of related transactions such as license agreements with academic and nonprofit institutions; research and development services agreements; clinical trial agreements; and manufacture, supply, and distribution agreements. Dr. Hovijitra has successfully guided many leading companies through significant transactions. These include Amphastar’s asset purchase from Lilly, Arcellx’s collaboration with Kite, IGM Biosciences’ collaboration with Sanofi, Dren Bio’s collaboration with Pfizer, and Vividion Therapeutics’ collaboration with Roche among others. His expertise also extends to facilitating impactful collaborations for Vertex Pharmaceuticals and Denali Therapeutics with leading entities, and guiding companies like Arrinex and Akarna Therapeutics through successful acquisitions. Previously, Norm worked as a patent agent at the firm, focusing on patent preparation and prosecution, research related to intellectual property, and due diligence matters in the life sciences and clean technology industries. Norm received his Ph.D. in chemical engineering at Stanford University, where he gained research experience in fermentation, molecular biology, and biochemistry. His graduate work focused on the production and characterization of membrane proteins and lipids.
